Iktos Secures €2.5M Grant Funding to Accelerate AI-Driven Drug Discovery Innovations

Iktos, a recognized leader in artificial intelligence and robotic solutions for medicinal chemistry and new drug design, is excited to announce the successful raise of 2,500,000 in additional funding. This new injection of capital underpins our continued commitment to transforming pharmaceutical R&D and further accelerating the drug discovery journey. By harnessing the power of our groundbreaking generative AI solution, we enable the in silico design of molecules that meet all the success criteria of a small molecule discovery project, offering major productivity gains in upstream pharmaceutical research. With our state-of-the-art SaaS platforms, Makya™ for generative design and Spaya™ for retrosynthesis, coupled with strategic pharma collaborations, we are uniquely positioned to expedite the development of promising new compounds. This recent funding empowers Iktos to push the boundaries further: enhancing the capabilities of Iktos Robotics—our AI-driven synthesis automation platform—and advancing our pipeline targeting oncology as well as auto-immune and inflammatory diseases. It is a testament to the trust the scientific and investment communities place in our innovative approach and the tangible results we have delivered over recent years. Following our notable milestones, including the completion of a 15.5M€ Series A financing round in March 2023 and the strategic acquisition of Synsight in July 2024 to integrate a cutting-edge biology platform, this new funding will accelerate our R&D efforts and widen the impact of our technologies. Ultimately, this investment will not only fuel further innovation at Iktos, but also drive forward the discovery of life-changing therapeutics that will benefit patients and pave the way for a future where artificial intelligence and robotics are at the forefront of drug discovery.